PT  - JOURNAL ARTICLE
AU  - PATRIZIA FERRONI
AU  - MARIO ROSELLI
AU  - ILARIA PORTARENA
AU  - VINCENZO FORMICA
AU  - SILVIA RIONDINO
AU  - FRANCESCA LA FARINA
AU  - LEOPOLDO COSTARELLI
AU  - ANTONIA MELINO
AU  - GIOIA MASSIMIANI
AU  - FRANCESCO CAVALIERE
AU  - RAFFAELE PALMIROTTA
AU  - FIORELLA GUADAGNI
TI  - Plasma Plasminogen Activator Inhibitor-1 (PAI-1) Levels in Breast Cancer – Relationship with Clinical Outcome
DP  - 2014 Mar 01
TA  - Anticancer Research
PG  - 1153--1161
VI  - 34
IP  - 3
4099  - http://ar.iiarjournals.org/content/34/3/1153.short
4100  - http://ar.iiarjournals.org/content/34/3/1153.full
SO  - Anticancer Res2014 Mar 01; 34
AB  - Background: Signaling pathways triggered by increased thrombin or plasminogen activator inhibitor-1 (PAI-1) expression drastically alter the tumor microenvironment, contributing to an adverse outcome. This study aimed to evaluate the prognostic value of coagulation/fibrinolytic activities in breast cancer (BC). Materials and Methods: Coagulation/fibrinolytic activities were investigated in 187 patients with breast cancer, with respect to possible associations with clinicopathological features and survival outcomes. Results: Levels of plasma PAI-1 (p<0.001), D-dimer (p=0.037) and activated protein C-dependent thrombin generation (p=0.003) were higher in women with breast cancer compared to 187 healthy women. PAI-1 directly correlated with D-dimer levels (p=0.009) and Ki67 expression (p=0.027), which were both predictors of elevated PAI-1 levels at multivariate regression analysis. Cox analysis demonstrated that an elevated plasma PAI-1 level had a negative prognostic impact in terms of relapse-free (hazard ratio=2.5, p=0.021) and overall survival (hazard ratio=2.7, p=0.002). Conclusion: Determination of plasma PAI-1 levels might provide important prognostic information in risk stratification and survival outcomes for patients with breast cancer.